As I have mentioned before, there are treatment options that far surpass the MANF mechanisms for treating the same diseases. Medical advancement is passing up MANF. Treatment options have a "time table" until better options present themselves. Just go look at the indications that MANF can treat and then look at the newer options that are presently either in trials or already at market. The reason BP never picked it up after all this time are the better , more contemporary options available. They have no interest.